Drugs such as Ozempic and Wegovy are delivering significant results for millions, but the weight loss isnt targeted
Figure 23: Photograph of Professor Graeme Bell in San Francisco taken by Mitsuko Seino in the parking lot of Chiron Corporation, 1984, credit: Accili, Bell
Injectables generally provide more predictable systemic exposure and have the strongest evidence for substantial, sustained weight loss
Common reasons include BMI not meeting requirements, missing documentation, no qualifying comorbidities, excluded benefits, incomplete prior authorization, or step therapy requirements
And with more than half of the global population (51% or over 4 billion people) predicted to be either overweight or living with obesity by 2035, investment in obesity drugs is forecast to rise by a compound annual growth rate of 35%38% between 2023 and 2027.9,10 While some GLP-1 treatments currently in the pipeline are set to reach the market in oral tablet form, autoinjectors and pen injectors currently at the forefront of GLP-1 delivery will continue to deliver multiple patient benefits across this significantly expanded market segment
Weight loss surgery, or bariatric surgery, is also an option for some people with a need to lose weight
